Your session is about to expire
← Back to Search
Cannabinoid
CBD for Youth Alcoholism
Phase 2
Waitlist Available
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 16 to 22
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up changes 3 hours after administration of 600mg cbd vs. placebo
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This trial is testing CBD, a compound from cannabis that doesn't cause a high, to help young people aged 16-22 who have alcohol addiction. The study will see if taking 600 mg of CBD can reduce cravings and anxiety related to alcohol use. Participants will be given either CBD or a non-active substance before undergoing brain scans and behavioral tests. Cannabidiol (CBD) has shown promise in decreasing alcohol consumption.
Who is the study for?
This trial is for young people aged 16-22, whether they drink alcohol or not. It's designed to see if CBD can help with youth alcohol use disorder. Participants will be involved in the study for about a month.
What is being tested?
The study tests the effects of cannabidiol (CBD) on youth with alcohol use issues using a double-blind method where neither researchers nor participants know who gets CBD or placebo during parts of the trial.
What are the potential side effects?
While not explicitly listed here, common side effects of CBD may include tiredness, diarrhea, changes in appetite/weight. However, each individual might experience different reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 16 and 22 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ changes 3 hours after administration of 600mg cbd vs. placebo
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~changes 3 hours after administration of 600mg cbd vs. placebo
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Alcohol cue reactivity (lab-based paradigm)
Alcohol cue reactivity neural activation
GABA
+1 moreSide effects data
From 2022 Phase 2 & 3 trial • 90 Patients • NCT0438761729%
Tiredness
20%
Constipation
18%
Drowsiness
11%
Poor sleep
11%
Dizziness
9%
Poor Appetite
9%
Headache
4%
Nausea
4%
Itching
2%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control Group
CBD Oil Group
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Placebo, Then CannabidiolExperimental Treatment1 Intervention
Group II: Cannabidiol, Then PlaceboExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol
FDA approved
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for alcoholism often target the brain's reward and stress systems to reduce cravings and withdrawal symptoms. Cannabidiol (CBD) modulates the endocannabinoid system, which may help reduce alcohol cravings and anxiety, making it a promising candidate for treating alcoholism.
Other treatments include naltrexone, which blocks opioid receptors to reduce the rewarding effects of alcohol, and acamprosate, which stabilizes chemical signaling in the brain to alleviate withdrawal symptoms. Understanding these mechanisms is crucial for tailoring treatments to individual patients, potentially improving outcomes by addressing specific neurobiological pathways involved in addiction.
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
Find a Location
Who is running the clinical trial?
Medical University of South CarolinaLead Sponsor
977 Previous Clinical Trials
7,400,943 Total Patients Enrolled
46 Trials studying Alcoholism
5,047 Patients Enrolled for Alcoholism
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 16 and 22 years old.You are a drinker or a non-drinker of alcohol.
Research Study Groups:
This trial has the following groups:- Group 1: Cannabidiol, Then Placebo
- Group 2: Placebo, Then Cannabidiol
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.